IL2 and cancer: Although the first approach led to efficient activation of target cell types and generated remarkable antitumor responses in mouse models without causing VLS (9, 43, 44), it has nonetheless been very difficult to translate the strategy into a viable clinical treatment for patients with cancer, largely because of challenges to consistent formulation and lack of stability of the IL-2/antibody complexes in vivo (44, 45).